Thursday, March 16, 2017 4:27:59 PM
At the end of the year, we had approximately 12.9 million common shares outstanding. During the first quarter of 2017 to date, we raised an additional $1.7 million of net proceeds using our ATM program. And we now have approximately 13.5 million common shares outstanding.
After year-end, we reported top line results from our confirmatory Phase 3 study of Macrilen for the evaluation of Adult Growth Hormone Deficiency or AGHD. We were disappointed by the top line results as we failed to meet one of the co-primary endpoints of the study.
However, our disappointment soon gave way to optimism, as we evaluated the full data from the clinical trial. We concluded together with our panel of independent experts that Macrilen works even better than we had expected. And that it demonstrated performance that we believe is supportive of achieving registration with the U.S. Food and Drug Administration.
We will discuss the results of the clinical trial in our conclusions with the FDA at the end of March. And hope to have a timely decision regarding the future of the development of this drug. If the FDA agrees with us, we expect to be able to file the NDA or new drug application early third quarter, and if it is approved begin commercializing the product in first quarter of 2018.
Recent CSCI News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/23/2024 11:30:23 AM
- COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs • GlobeNewswire Inc. • 09/23/2024 11:30:00 AM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 09/06/2024 06:04:41 PM
- COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency • GlobeNewswire Inc. • 08/27/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:05:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:05:17 PM
- COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/13/2024 12:05:00 PM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM